20152024年上海市黄浦区14岁及以上人群急性呼吸道感染病例多病原流行特征分析

Analyses of the epidemiological characteristics of multiple pathogens in people aged 14 years and above with acute respiratory infection in Huangpu District of Shanghai from 2015 to 2024

  • 摘要:
    目的 了解上海市黄浦区发热门诊急性呼吸道感染流感样病例(ILI)在2015—2024年8种主要呼吸道病原体的流行病学特征,为呼吸道疾病的防治提供科学依据。
    方法 采用回顾性研究方法,对2015—2024年黄浦区符合ILI定义的人群进行登记,采集呼吸道鼻咽拭子并开展检测,共纳入8种呼吸道病毒,分别是甲型流感病毒、乙型流感病毒、腺病毒、肠道病毒/人鼻病毒、人副流感病毒、人冠状病毒、呼吸道合胞病毒、人偏肺病毒。
    结果 2015—2019年共检测ILI病例344例,单一病原阳性率为55.81%(192/344)。2023—2024年共检测1 557例ILI病例,单一病原阳性率为36.74%(572/1 557)。2023—2024年ILI病例的单一病原阳性率较2015—2019年有所下降 (χ2 =42.66,P<0.001),其中甲型流感病毒阳性率下降(χ2 =74.43,P<0.001),人副流感病毒阳性率上升(χ2 =8.66,P=0.003),差异均有统计学意义。甲型流感病毒的流行强度在夏季降低,而人副流感病毒的流行在夏季和秋季上升。2015—2024年ILI监测人群中,不同性别肠道病毒/人鼻病毒阳性率差异具有统计学意义(χ2 =22.38,P<0.001),且男性阳性率高于女性。不同年龄组单一病原阳性率差异无统计学意义(χ2=4.42,P=0.110),不同年龄段患者肠道病毒/人鼻病毒、甲型流感病毒和乙型流感病毒、人副流感病毒相比较差异有统计学意义(均P<0.05)。肠道病毒/人鼻病毒多见于15~<25岁年龄组(10.93%),而甲型流感病毒和人副流感病毒在≥60岁人群中阳性率最高(21.24%和4.77%),乙型流感病毒在25~<60岁年龄组人群中阳性率最高(11.26%)。52.63%的双重感染发生在冬季,双重感染的主要病原为肠道病毒/人鼻病毒(9例)和人冠状病毒(6例),最常见的双重感染组合为甲型流感病毒与肠道病毒/人鼻病毒。
    结论 2023—2024年黄浦区ILI呼吸道病原体的流行较2015—2019年有明显的波动。在加强流感监测和预防的同时,还应关注人副流感病毒等呼吸道病原体的流行,这对未来的研究和监测、疫苗规划和公共卫生政策制定具有深远意义。

     

    Abstract:
    Objective To analyze the epidemiological characteristics of 8 major respiratory pathogens in influenza-like illness (ILI) cases with acute respiratory infections at fever clinics in Huangpu District, Shanghai from 2015 to 2024, and to provide a scientific basis for the prevention and treatment of respiratory diseases.
    Methods A retrospective study was conducted in Huangpu District. Individuals meeting the case definition of ILI from 2015 to 2024 was registered. Their nasopharyngeal swabs were collected for pathogen detection. A total of 8 respiratory viruses were tested, including Influenza A virus (Flu A), Influenza B virus (Flu B), adenovirus (ADV), enterovirus/human rhinovirus (EV/HRV), human parainfluenza virus (HPIV), human coronavirus (HCoV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV).
    Results From 2015 to 2019, a total of 344 ILI cases were tested, of which 192 out of 344 cases (55.81%) were tested positive for single respiratory pathogen. From 2023 to 2024, 1 557 ILI cases were tested, with 572 out of 1 557 cases (36.74%) being positive for single pathogen. From 2023 to 2024, the positive rate of single pathogen in ILI cases was significantly lower than that in 2015‒2019 (χ2=42.66, P<0.001). Specifically, the positive rate of Flu A (χ2=74.43, P<0.001) decreased, while that of HPIV (χ2=8.66, P=0.003) increased, both with statistically significant differences. According to the seasonal pattern, the epidemic intensity of Flu A decreased in summer, while that of HPIV increased in summer and autumn. Demographic results showed statistically significant differences in the positive rates of EV/HRV between genders (χ2=22.38, P<0.001), with males exhibiting a higher positive rate than females. No statistically significant differences were identified in the positive rates of single pathogen among different age groups (χ2=4.42, P=0.110). Nevertheless, statistically significant differences were noted when comparing the positive rates of EV/HRV, Flu A, Flu B and HPIV across different age groups (P<0.05). EV/HRV was more commonly detected in the 15‒<25 age group (10.93%), while Flu A and HPIV had the highest positive rates in the ≥60 age group (21.24% and 4.77%). Flu B had the highest positive rate in the 25‒<60 age group (11.26%). 52.63% of cases with co-infections occurred during winter, with the primary pathogens involved being EV/HRV (9 cases) and HCoV (6 cases). The most prevalent combination of co-infection was Flu A with EV/HRV.
    Conclusion The prevalence of respiratory pathogens among ILI cases from 2023 to 2024 exhibited notable fluctuations compared to that from 2015 to 2019. Therefore, influenza surveillance should be strengthened, and attention should also be paid to the prevalence of respiratory pathogens such as HPIV. These findings have profound implications for future research, surveillance, vaccine planning, and public health policy making.

     

/

返回文章
返回